ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2202

Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies

Alhanouf Alsaleem1, Wafaa Abdulghaffar2, Lujain Akbar3, Meshal Alhassan4, Fatimah Alkhars5 and Sulaiman Al-Mayouf6, 1KFSH&RC, Riyadh, Saudi Arabia, 2KFSHRC, RIYADH, RIYADH, 3RIYADH, RIYADH, Saudi Arabia, 4Imam Abdulrahman Bin Faisal University, DAMMAM, 5Maternity and children hospital, ALHASSA, 6KFSHRRC, Riyadh, Saudi Arabia

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, genetics, Pediatric rheumatology, Periodic Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Loss of negative regulator in ISG15 and USP18 results in recently described immunodysregulatory disorders with diversity of clinical characteristics related to enhanced IFN-a/b immunity. We aim to describe the phenotype, genotype and outcome of Saudi children with proved pathogenic mutation of ISG15/USP18 genes.

Methods: Multicenter descriptive study of pediatric patients with final genetically confirmed type I interferonopathies and ISG15/USP18 gene mutation. Medical records were reviewed for demographic, clinical and genetic data.

Results: Total of fourteen patients from unrelated six Saudi families; only nine had proven gene mutation. Five patients (55%) presented within the first two years. Median age of disease onset was twenty-four months. Constitutional features were found in all patients. The most frequent organ involvements were neurology (77%), pulmonary (66%), skin abscess (55%), and musculoskeletal (44%). All patients had elevated inflammatory markers. Two patients had severe macrophage activation syndrome. Autoantibodies were evident in five patients; two of them developed lupus like disease. Four patients had abnormal immunology work up and three had recurrent infections. Genetic sequencing identified ISG15 gene mutation in eight patients, of which all had novel genetic variants. Only one patient had USP18 gene mutation with previously reported variant. Majority of the patients were treated with corticosteroids (n=8), immunoglobulin (n=3), Janus kinase inhibitors (n=2), in addition to various other immunosuppressive agents. Only one patient died with multiorgan failure.

Conclusion: Loss of negative regulator in ISG15 and USP18 genes highlight a recently described interferon mediated disease. This the first and largest cohort from the Arab region to date. In this report we expand the clinical and genetic spectrum with novel identified variants of this seldom reported disease entity along with diversity of disease severity and outcome.


Disclosures: A. Alsaleem: None; W. Abdulghaffar: None; L. Akbar: None; M. Alhassan: None; F. Alkhars: None; S. Al-Mayouf: None.

To cite this abstract in AMA style:

Alsaleem A, Abdulghaffar W, Akbar L, Alhassan M, Alkhars F, Al-Mayouf S. Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evolving-phenotypic-and-genotypic-spectrum-of-human-isg15-and-usp18-deficiencies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evolving-phenotypic-and-genotypic-spectrum-of-human-isg15-and-usp18-deficiencies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology